RxDoctor Payments Data

Claire Gebara

Primary Care · Waterford, MINPI 1245830264

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 92.8% of the total across 286 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 44 manufacturers, the largest accounting for just 17.1% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $3,510, 4.8 times the $726 reported in 2021. Among primary care clinicians in MI with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$8,987in general payments, 2019–2025

Across 286 payments — averaging $31.42 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Teleflex LLC$2K
  • Sumitomo Pharma America, Inc.$929
  • Johnson & Johnson$578
  • Ferring Pharmaceuticals Inc.$545
  • Urogen Pharma, Inc.$532
  • Antares Pharma, Inc.$433
  • plus $4K from 38 others

What the payments were for

  • Travel & lodging$2403%
  • Food & beverage$8,34393%
  • Education$2523%
  • Gifts$1522%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,987 in reported general payments places this provider in the 95th percentile of 292 primary care providers in Michigan.

See all primary care providers in Michigan

Most prescribed under Part D

DrugClaimsCost to plans & patients
MyrbetriqMirabegron103$94,187
GemtesaVibegron55$57,334
Mirabegron ErMirabegron36$28,861
ElmironPentosan Polysulfate Sodium17$25,411
Tamsulosin Hcl901$19,935
Finasteride365$7,155
Solifenacin Succinate94$4,559
Tolterodine Tartrate ErTolterodine Tartrate46$4,220
Potassium Citrate ErPotassium Citrate38$4,028
Dutasteride59$3,313
Alfuzosin Hcl ErAlfuzosin Hcl93$3,226
Testosterone Cypionate43$2,237
Dutasteride-TamsulosinDutasteride/Tamsulosin Hcl13$1,833
Fesoterodine Fumarate ErFesoterodine Fumarate17$1,699
Oxybutynin Chloride ErOxybutynin Chloride58$1,629

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncMyrbetriq$220$94,187103 claims
Sumitomo Pharma America, Inc.Gemtesa$929$57,33455 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 292 primary care providers in Michigan.

Other primary care in Waterford

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →